Globus Medical (GMED) 10-Q 30 Apr 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 14, 2014
Document Information	'	'
Entity Registrant Name	'GLOBUS MEDICAL INC	'
Entity Central Index Key	'0001237831	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	94,067,569

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
ASSETS	'	'
Cash and cash equivalents	$104,602	$89,962
Short-term marketable securities	176,204	148,962
Accounts receivable, net of allowances of $1,504 and $1,581, respectively	63,224	62,414
Inventories	72,507	70,350
Prepaid expenses and other current assets	4,744	5,080
Income taxes receivable	1,142	2,723
Deferred income taxes	38,478	37,317
Total current assets	460,901	416,808
Property and equipment, net of accumulated depreciation of $104,817 and $99,910, respectively	65,643	64,150
Long-term marketable securities	24,151	36,528
Intangible assets, net	29,404	29,537
Goodwill	18,372	18,372
Other assets	951	909
Total assets	599,422	566,304
LIABILITIES AND EQUITY	'	'
Accounts payable	9,446	10,073
Accounts payable to related-party	3,840	2,656
Accrued expenses	49,152	51,125
Income taxes payable	8,654	2,358
Business acquisition liabilities, current	1,399	1,730
Total current liabilities	72,491	67,942
Business acquisition liabilities, net of current portion	15,621	15,528
Deferred income taxes	5,130	6,385
Other liabilities	4,115	4,089
Total liabilities	97,357	93,944
Commitments and contingencies (Note 12)	'	'
Equity:	'	'
Common stock; $0.001 par value. Authorized 785,000 shares; issued and outstanding 94,065 and 93,443 shares at March 31, 2014 and December 31, 2013, respectively	94	93
Additional paid-in capital	162,554	153,987
Accumulated other comprehensive loss	-1,011	-1,009
Retained earnings	340,428	319,289
Total equity	502,065	472,360
Total liabilities and equity	$599,422	$566,304

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Current Assets:	'	'
Allowance for doubtful accounts	$1,504	$1,581
Property, Plant and Equipment, Net	'	'
Accumulated depreciation	$104,817	$99,910
Equity:	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	785,000,000	785,000,000
Common stock, shares issued	94,065,352	93,442,753
Common stock, shares outstanding	94,065,352	93,442,753

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Sales	$114,210	$105,018
Cost of goods sold	25,312	23,493
Gross profit	88,898	81,525
Operating expenses:	'	'
Research and development	7,443	6,847
Selling, general and administrative	46,678	45,397
Provision for litigation, net	2,535	50
Total operating expenses	56,656	52,294
Operating Income	32,242	29,231
Other income, net	245	279
Income before income taxes	32,487	29,510
Income tax provision	11,348	9,619
Net Income	$21,139	$19,891
Earnings per share:	'	'
Basic	$0.23	$0.22
Diluted	$0.22	$0.21
Weighted average shares outstanding:	'	'
Basic	93,715	91,805
Dilutive stock options	1,457	1,768
Diluted	95,172	93,573
Anti-dilutive stock equivalents excluded from weighted average calculation	1,235	3,184

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement of Comprehensive Income [Abstract]	'	'
Net income	$21,139	$19,891
Other comprehensive income/(loss):	'	'
Unrealized gain/(loss) on marketable securities, net of tax	1	-18
Foreign currency translation loss	-3	-563
Total other comprehensive loss	-2	-581
Comprehensive Income	$21,137	$19,310

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income	$21,139	$19,891
Adjustments to reconcile net income to net cash provided by operating activities	'	'
Depreciation and amortization	5,297	4,610
Provision for excess and obsolete inventories	1,813	2,000
Stock-based compensation	1,927	1,312
Allowance for doubtful accounts	89	54
Change in deferred income taxes	-2,415	-1,900
(Increase)/decrease in:	'	'
Accounts receivable	-812	-6,197
Inventories	-3,993	-7,009
Prepaid expenses and other assets	239	-850
Increase/(decrease) in:	'	'
Accounts payable	-1,096	-320
Accounts payable to related party	1,184	1,322
Accrued expenses and other liabilities	-2,015	-5,490
Income taxes payable/receivable	7,875	10,853
Net cash provided by operating activities	29,232	18,276
Cash flows from investing activities:	'	'
Purchases of marketable securities	-75,343	-93,187
Maturities of marketable securities	46,250	0
Sales of marketable securities	14,280	0
Purchases of property and equipment	-6,164	-6,772
Net cash used in investing activities	-20,977	-99,959
Cash flows from financing activities:	'	'
Payment of business acquisition liabilities	-200	-400
Proceeds from issuance of common stock	3,855	885
Excess tax benefit related to nonqualified stock options	2,786	303
Net cash provided by financing activities	6,441	788
Effect of foreign exchange rate on cash	-56	38
Net increase/(decrease) in cash and cash equivalents	14,640	-80,857
Cash and cash equivalents, beginning of period	89,962	212,400
Cash and cash equivalents, end of period	104,602	131,543
Supplemental disclosures of cash flow information:	'	'
Interest paid	13	17
Income taxes paid	$3,168	$418

BACKGROUND_AND_SUMMARY_OF_SIGN

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2014
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Background and Summary of Significant Accounting Policies	'
	BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) The Company
	Globus Medical, Inc., together with its subsidiaries, is a medical device company focused exclusively on the design, development and commercialization of musculoskeletal implants. We are currently focused on implants that promote healing in patients with spine disorders. Since our inception in 2003, we have launched over 120 products and offer a product portfolio addressing a broad array of spinal pathologies.
	We are headquartered in Audubon, Pennsylvania and market and sell our products through our exclusive sales force in the United States, Europe, India, South Africa, Australia, Central & South America and the Middle East. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
	The terms “the Company,” “Globus,” “we,” “us” and “our” refer to Globus Medical, Inc. and, where applicable, our consolidated subsidiaries.
	(b) Basis of Presentation
	The accompanying interim unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	In the opinion of management, the statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results for the three-month periods presented. The results of operations for any interim period are not indicative of results for the full year. Certain reclassifications have been made to prior period statements to conform to the current year presentation.
	(c) Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held. All intercompany balances and transactions are eliminated in consolidation.
	(d) Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
	(e) Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper and asset-backed securities, and are classified as available-for-sale as of March 31, 2014. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
	(f) Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
	(g) Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.

ACQUISITIONS

ACQUISITIONS	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure	'
	ACQUISITIONS
	On December 23, 2013, we entered into an asset purchase agreement with a small robotics development company, pursuant to which we acquired substantially all of its assets for $16.8 million. In addition to the initial purchase price, we may be obligated to make a milestone payment and revenue sharing payments based upon a percentage of net sales of certain products based on the intellectual property we acquired in the transaction. The acquired company was privately held and is focused on developing a next generation surgical robotic positioning platform for spine, brain and other therapeutic markets. The technology is intended to enable surgeons to perform minimally invasive and percutaneous surgical procedures with greater accuracy, safety and reproducibility than is currently available. We accounted for this purchase as a business combination, and as a result, recorded goodwill of $3.0 million.
	This acquisition, which expanded our product pipeline, did not have a material effect on our consolidated net sales or operating income for the year ended December 31, 2013 or for the three months ended March 31, 2014. The assets acquired and liabilities assumed as a result of the acquisition were included in our consolidated balance sheet as of the acquisition date. The purchase price for this acquisition was allocated to the identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date. The fair value assigned to identifiable intangible assets acquired was determined primarily by using the income approach, which discounts expected future cash flows to present value using estimates and assumptions determined by management. Purchased identifiable intangible assets are amortized on a straight-line basis over their respective estimated useful lives. The excess purchase price over the value of the net tangible and identifiable intangible assets was recorded as goodwill.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2014
Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure	'
	INTANGIBLE ASSETS
	A summary of intangible assets as of March 31, 2014 is presented below:
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Customer relationships & other intangibles	9.5	3,623		(962		)	2,661
	Patents	17	2,420		(237		)	2,183
	Total intangible assets		$	30,603	$	(1,199	)	$	29,404
	A summary of intangible assets as of December 31, 2013 is presented below:
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Customer relationships & other intangibles	9.5	3,623		(864		)	2,759
	Patents	17	2,420		(202		)	2,218
	Total intangible assets		$	30,603	$	(1,066	)	$	29,537

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	3 Months Ended
	Mar. 31, 2014
Marketable Securities [Abstract]	'
Marketable Securities	'
	MARKETABLE SECURITIES
	The composition of our short-term and long-term marketable securities as of March 31, 2014 is as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	79,191	$	41	$	(2	)	$	79,230
	Corporate debt securities	Less than 1	66,299		28		(24		)	66,303
	Commercial paper	Less than 1	30,667		5		(1		)	30,671
	Total short-term marketable securities		$	176,157	$	74	$	(27	)	$	176,204
	Long-term:
	Municipal bonds	2-Jan	$	6,340	$	2	$	(2	)	$	6,340
	Corporate debt securities	2-Jan	10,582		9		(6		)	10,585
	Asset backed securities	2-Jan	7,224		2		—			7,226
	Total long-term marketable securities		$	24,146	$	13	$	(8	)	$	24,151
	Our short-term and long-term marketable securities as of December 31, 2013 were as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	77,342	$	17	$	(15	)	$	77,344
	Corporate debt securities	Less than 1	35,525		15		(11		)	35,529
	Commercial paper	Less than 1	36,083		6		—			36,089
	Total short-term marketable securities		$	148,950	$	38	$	(26	)	$	148,962
	Long-term:
	Municipal bonds	2-Jan	$	12,304	$	13	$	(1	)	$	12,316
	Corporate debt securities	2-Jan	17,533		27		—			17,560
	Asset backed securities	2-Jan	6,651		2		(1		)	6,652
	Total long-term marketable securities		$	36,488	$	42	$	(2	)	$	36,528

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	FAIR VALUE MEASUREMENTS
	Under the accounting for fair value measurements and disclosures, fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:
	Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities;
	Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and
	Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques.
	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	March 31,		Level 1		Level 2		Level 3
		2014
	Assets
	Cash equivalents	$	30,686	$	12,359	$	18,327	$	—
	Municipal bonds	85,570		—		85,570		—
	Corporate debt securities	76,888		—		76,888		—
	Commercial paper	30,671		—		30,671		—
	Asset-backed securities	7,226		—		7,226		—
	Liabilities
	Acquisition-related contingent consideration	14,092		—		—		14,092
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2013
	Assets
	Cash equivalents	$	20,363	$	800	$	19,563	$	—
	Municipal bonds	89,660		—		89,660		—
	Corporate debt securities	53,089		—		53,089		—
	Commercial paper	36,089		—		36,089		—
	Asset-backed securities	6,652		—		6,652		—
	Liabilities
	Acquisition-related contingent consideration	14,177		—		—		14,177
	We reclassified $18.3 million of cash equivalents reported as of December 31, 2013 from Level 1 to Level 2. The reclassification adjusted the December 31, 2013 balance to the appropriate Level categories which is consistent with the presentation as of March 31, 2014. Neither the inputs nor the valuation methods have changed during the three month period ended March 31, 2014.
	Acquisition-related contingent consideration represents our contingent milestone, performance and revenue-sharing payment obligations related to our acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of acquisition-related contingent consideration uses assumptions we believe would be made by a market participant. We assess these estimates on an ongoing basis as additional data impacting the assumptions is obtained. Changes in the fair value of acquisition-related contingent consideration related to updated assumptions and estimates are recognized within research and development and selling, general and administrative expenses in the consolidated statements of income.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	INVENTORIES
	(In thousands)	March 31, 2014		December 31, 2013
	Raw materials	$	1,870	$	1,369
	Work in process	2,411		2,820
	Finished goods	68,226		66,161
	Total inventories	$	72,507	$	70,350

ACCRUED_EXPENSES

ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	ACCRUED EXPENSES
	(In thousands)	March 31,		December 31,
		2014		2013
	Compensation and other employee-related costs	$	11,852	$	17,428
	Legal and other settlements and expenses	26,509		23,765
	Non-income taxes	3,427		2,938
	Other	7,364		6,994
	Total accrued expenses	$	49,152	$	51,125

DEBT

DEBT	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt	'
	DEBT
	Line of Credit
	In May 2011, and as amended in March 2012 and May 2013, we entered into a credit agreement with Wells Fargo Bank related to a revolving credit facility that provided for borrowings up to $50.0 million. At our request, and with the approval of the bank, the amount of borrowings available under the revolving credit facility can be increased to $75.0 million. The revolving credit facility includes up to a $25.0 million sub-limit for letters of credit. The revolving credit facility was extended to May 2015. Cash advances bear interest at our option either at a fluctuating rate per annum equal to the daily LIBOR in effect for a one-month period plus 0.75%, or a fixed rate for a one- or three-month period equal to LIBOR plus 0.75%. The credit agreement governing the revolving credit facility also subjects us to various restrictive covenants, including the requirement to maintain maximum consolidated leverage. The covenants also include limitations on our ability to repurchase shares, to pay cash dividends or to enter into a sale transaction. As of March 31, 2014, we were in compliance with all covenants under the credit agreement, there were no outstanding borrowings under the revolving credit facility and available borrowings were $50.0 million. The revolving credit facility is subject to an unused commitment fee of 0.10% of the unused portion. We may terminate the credit agreement at any time on ten days’ notice without premium or penalty.

EQUITY

EQUITY	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Equity	'
	EQUITY
	Our amended and restated Certificate of Incorporation provides for a total of 785,000,000 authorized shares of common stock. Of the authorized number of shares of common stock, 500,000,000 shares are designated as Class A common stock (“Class A Common”), 275,000,000 shares are designated as Class B common stock (“Class B Common”) and 10,000,000 shares are designated as Class C common stock (“Class C Common”).
	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common			Class B			Total
					Common
	March 31, 2014	67,187,796			26,877,556			94,065,352
	December 31, 2013	66,065,197			27,377,556			93,442,753
	The following table summarizes changes in total equity:
		Three Months Ended
	(In thousands)	March 31,
		2014
	Total equity, beginning of period	$	472,360
	Net income	21,139
	Stock-based compensation	1,927
	Exercise of stock options	3,855
	Excess tax benefit of nonqualified stock options	2,786
	Other comprehensive loss	(2		)
	Total equity, end of period	$	502,065
	The tables below present the changes in each component of accumulated other comprehensive income/(loss), including current period other comprehensive income/(loss) and reclassifications out of accumulated other comprehensive income/(loss):
	(In thousands)	Unrealized gain/(loss) on marketable securities, net of tax				Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive income/(loss), net of tax, at December 31, 2013	$	32			$	(1,041	)	$	(1,009	)
	Other comprehensive loss before reclassifications	(5		)		(3		)	(8		)
	Amounts reclassified from accumulated other comprehensive income, net of tax	6				—			6
	Other comprehensive income/(loss), net of tax	1				(3		)	(2		)
	Accumulated other comprehensive income/(loss), net of tax, at March 31, 2014	$	33			$	(1,044	)	$	(1,011	)
	(In thousands)	Unrealized gain/(loss) on marketable securities, net of tax				Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive loss, net of tax, at December 31, 2012	$	—			$	(767	)	$	(767	)
	Other comprehensive loss	(18		)		(563		)	(581		)
	Other comprehensive loss, net of tax	(18		)		(563		)	(581		)
	Accumulated other comprehensive loss, net of tax, at March 31, 2013	$	(18	)		$	(1,330	)	$	(1,348	)

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	STOCK-BASED COMPENSATION
	We have three stock plans, but no additional shares will be issued under our Amended and Restated 2003 Stock Plan and our 2008 Stock Plan, leaving the 2012 Equity Incentive Plan (the "2012 Plan") as the only remaining active stock plan.  The purpose of these stock plans was, and the 2012 Plan is, to provide incentive to employees, directors, and consultants of Globus.  The Plans are administered by the Board or its delegates. The number, type of option, exercise price, and vesting terms are determined by the Board or its delegates in accordance with the terms of the Plans. The options granted expire on a date specified by the Board, but generally not more than ten years from the grant date. Option grants to employees generally vest monthly over a four-year period.
	The 2012 Plan was approved by our Board in March 2012, and by our stockholders in June 2012. Under the 2012 Plan, the aggregate number of shares of Class A Common that may be issued subject to options and other awards is equal to the sum of (i) 3,076,923 shares, (ii) any shares available for issuance under the 2008 Plan as of March 13, 2012, (iii) any shares underlying awards outstanding under the 2008 Plan as of March 13, 2012 that, on or after that date, are forfeited, terminated, expired or lapse for any reason, or are settled for cash without delivery of shares and (iv) starting January 1, 2013, an annual increase in the number of shares available under the 2012 Plan equal to up to 3% of the number of shares of our common and preferred stock outstanding at the end of the previous year, as determined by our Board. The number of shares that may be issued or transferred pursuant to incentive stock options under the 2012 Plan is limited to 10,769,230 shares. The shares of Class A Common covered by the 2012 Plan are authorized but unissued shares, treasury shares or shares of common stock purchased on the open market.
	As of March 31, 2014, there were 6,533,666 shares of common stock available for future grants under the 2012 Plan.
	The weighted average grant date per share fair values of the options awarded to employees were as follows:
		Three Months Ended
		March 31,			March 31,
		2014			2013
	Weighted average grant date per share fair value	$	10.34		$	5.5
	Stock option activity during the three months ended March 31, 2014 is summarized as follows:
		Option Shares(thousands)		Weighted average exercise price			Weighted average remaining contractual life (years)	Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2013	4,886		$	10.04
	Granted	794		24.55
	Exercised	(623	)	6.19
	Forfeited	(72	)	13.79
	Outstanding at March 31, 2014	4,985		$	12.78		7.4	$	68,826
	Exercisable at March 31, 2014	2,513		$	8.26		5.8	$	46,110
	Compensation expense related to stock options granted to employees and non-employees under the Plans and the intrinsic value of stock options exercised was as follows:
		Three Months Ended
	(In thousands)	March 31,			March 31,
		2014			2013
	Compensation expense related to stock options	$	1,927		$	1,312
	Intrinsic value of stock options exercised	11,283			6,920
	As of March 31, 2014, there was $16.4 million of unrecognized compensation expense related to unvested employee stock options that are expected to vest over a weighted average period of three years.

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	INCOME TAXES
	In computing our income tax provision, we make certain estimates and management judgments, such as estimated annual taxable income or loss, annual effective tax rate, the nature and timing of permanent and temporary differences between taxable income for financial reporting and tax reporting, and the recoverability of deferred tax assets. Our estimates and assumptions may change as new events occur, additional information is obtained, or as the tax environment changes. Should facts and circumstances change during a quarter causing a material change to the estimated effective income tax rate, a cumulative adjustment is recorded.
	For the three-month periods ended March 31, 2014 and 2013, our effective income tax rates were 34.9% and 32.6%, respectively. The increase in our effective rate was primarily due to the effects of the timing of the American Taxpayer Relief Act of 2012 (“ATRA”), which favorably impacted the three months ended March 31, 2013, due to the inability to recognize the effect of the reinstated credit in 2012 (the period of qualifying activity), the increase in pre-tax income and other changes to the components of the annual effective tax rate calculation. On January 2, 2013, the ATRA was signed into law and reinstated the research and experimentation credit from January 1, 2012 through December 31, 2013. However, as the passage of the ATRA occurred in 2013, $0.8 million of the reinstated credit for the year ended December 31, 2012 was recognized during the three months ended March 31, 2013 in accordance with accounting guidance. As of March 31, 2014, the research and experimentation credit has not been extended for 2014, having an estimated 0.7% impact to the effective rate for the three months ended March 31, 2014.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	We are involved in a number of proceedings, legal actions, and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within our control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions prohibiting us from engaging in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. We record a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. While it is not possible to predict the outcome for most of the matters discussed, we believe it is possible that costs associated with them could have a material adverse impact on our consolidated earnings, financial position or cash flows.
	N-Spine, Synthes and DePuy Synthes Litigation
	In April 2010, N-Spine, Inc. and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. N-Spine, the patent owner, and Synthes USA, a licensee of the subject patent, allege that we infringe one or more claims of the patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. N-Spine and Synthes USA seek injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. This matter was stayed on July 14, 2011 pending the resolution of an inter partes reexamination on the asserted patent granted by the U.S. Patent and Trademark Office (“USPTO”) in February 2011. In December 2011, the examiner withdrew the original grounds of rejection of the asserted patent and we have appealed the examiner’s decision. In January 2014, the USPTO ruled on the appeal finding certain claims rejected in view of the prior art and affirming certain other claims. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	In a related matter, on January 8, 2014, Depuy Synthes Products, LLC (“Depuy Synthes”) filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Depuy Synthes alleges that we infringe one or more claims of the asserted patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. Depuy Synthes seeks injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. This matter is in its very early stages, and the probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC Litigation
	In July 2011, Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Synthes USA LLC, the patent owner, Synthes USA Products, LLC, a licensee to manufacture products of the subject patents, and Synthes USA Sales LLC, a licensee to sell products of the subject patents, allege that we infringed one or more claims of three patents by making, using, offering for sale or selling our COALITION®, INDEPENDENCE® and INTERCONTINENTAL® products. As a result of the acquisition of Synthes, Inc. by Johnson & Johnson, a motion was filed to change the plaintiff in this matter to DePuy Synthes in February 2013. On June 14, 2013, the jury in this case returned a verdict, finding that prior versions of the three products we previously sold did infringe on DePuy Synthes’ patents and awarding monetary damages in the amount of $16.0 million. The jury also upheld the validity of DePuy Synthes’ patents. There was no finding of willful infringement by Globus. This verdict does not impact our ability to conduct our business or have any material impact on our future revenues.
	We believe the facts and the law do not support the jury’s findings of infringement and patent validity and are seeking to overturn the verdict through the appeals process.
	As of December 31, 2013, we accrued $19.5 million in damages and other litigation-related costs related to this case, of which $1.3 million was included in provision for litigation, net (cost of goods sold, due to a write off of certain inventory which will not be sold due to the verdict) and $18.2 million was included in provision for litigation, net (operating expense). During the three months ended March 31, 2014, we accrued an additional $0.5 million in interest included in provision for litigation, net related to this litigation.
	L5 Litigation
	In December 2009, we filed suit in the Court of Common Pleas of Montgomery County, Pennsylvania against our former exclusive independent distributor L5 Surgical, LLC and its principals, seeking an injunction and declaratory judgment concerning certain restrictive covenants made to L5 by its sales representatives. L5 brought counterclaims against us alleging tortious interference, unfair competition and conspiracy. The injunction phase was resolved in September 2010, and this matter is now in the discovery phase of litigation on the underlying damages claims. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	NuVasive Infringement Litigation
	In October 2010, NuVasive, Inc. filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. NuVasive, the patent owner, alleges that we infringe one or more claims of three patents by making, using, offering for sale or selling our MARS 3V™ retractor for use in certain lateral fusion procedures. NuVasive seeks injunctive relief and an unspecified amount in damages. The litigation is currently in the dispositive motions phase. We intend to defend our rights vigorously. Additionally, we sought inter partes reexaminations of the three patents asserted by NuVasive in the USPTO, which were granted in April 2012. In August 2012, the examiner withdrew the original grounds of rejection of the patents asserted by NuVasive, and we are in the process of appealing the examiner’s decision. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	NuVasive Employee Litigation
	We have hired several employees who were formerly employed by NuVasive, Inc. In July 2011, NuVasive filed suit against us in the District Court of Travis County, Texas alleging that our hiring of one named former employee and other unnamed former employees constitutes tortious interference with its contracts with those employees, and with prospective business relationships, as well as aiding and abetting the breach of fiduciary duty. NuVasive is seeking compensatory damages, permanent injunction, punitive damages and attorneys’ fees. Trial is currently scheduled for May 2014. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	Bianco Litigation
	On March 21, 2012, Sabatino Bianco filed suit against us in the Federal District Court for the Eastern District of Texas claiming that we misappropriated his trade secret and confidential information and improperly utilized it in developing our CALIBER® product. Bianco alleges that we engaged in misappropriation of trade secrets, breach of contract, unfair competition, fraud and theft and seeks correction of inventorship, injunctive relief and exemplary damages. On April 20, 2012, Bianco filed a motion for a preliminary injunction, seeking to enjoin us from making, using, selling, importing or offering for sale our CALIBER® product. On November 15, 2012, the court denied Bianco’s motion for preliminary injunction. On October 1, 2013, Bianco amended his complaint to claim that his trade secrets and confidential information were also used improperly in developing our RISE® and CALIBER-L® products.
	On January 17, 2014, the jury in this case returned a verdict in favor of Bianco on a claim of misappropriation of trade secret. We accrued the verdict amount of $4.3 million as of December 31, 2013. The jury found against Bianco on the claims of breach of contract and disgorgement of profits. The court granted our motion for judgment as a matter of law and dismissed Bianco’s claims for unfair competition, fraud, and exemplary damages, and Bianco abandoned the claim of misappropriation of confidential information. Bianco’s claims of correction of inventorship, unjust enrichment, and permanent injunctive relief were not submitted to the jury. On March 7, 2014, the court denied Bianco’s claim for correction of inventorship and ruled he is not entitled to be named as a co-inventor on any of the patents at issue, and also denied his claim for unjust enrichment. On March 17, 2014, the court denied Bianco’s claim for permanent injunctive relief. Bianco’s claim for future damages, if any are permitted, will be determined by the court following a hearing currently scheduled in May 2014. Judgment has not yet been entered in this case.
	We do not expect the verdict to impact our ability to conduct our business or to have any material impact on our future revenues. We believe the facts and the law do not support the jury’s findings of misappropriation of trade secret and will seek to overturn the verdict in post-trial motions with the District Court and, if necessary, we will continue to do so through the appeals process.
	Altus Partners, LLC Litigation
	On February 20, 2013, Altus Partners, LLC filed suit against us in the U.S. District Court for the Eastern District of Pennsylvania for patent infringement.  Altus Partners alleged that we infringed one or more claims of U.S. Patent No. 8,162,989, which were issued on April 24, 2012, by making, using, offering for sale or selling our REVERE®, TRANSITION® and REVOLVE® products.  On April 7, 2014, we settled the litigation with Altus Partners and recognized a provision for litigation of $2.0 million.
	In addition, we are subject to legal proceedings arising in the ordinary course of business.

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related-Party Transactions	'
	RELATED-PARTY TRANSACTIONS
	We have contracted with a third-party manufacturer in which certain of our senior management and significant stockholders have or had ownership interests and leadership positions.
	We have purchased the following amounts of products and services from the supplier:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2014		2013
	Purchases from related-party supplier	$	4,850	$	5,132
	As of March 31, 2014 and December 31, 2013, we had $3.8 million and $2.7 million, respectively, of accounts payable due to the supplier.

SEGMENT_AND_GEOGRAPHIC_INFORMA

SEGMENT AND GEOGRAPHIC INFORMATION	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment And Geographic Information	'
	SEGMENT AND GEOGRAPHIC INFORMATION
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We globally manage the business within one reportable segment. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Products are sold principally in the United States.
	The following table represents total sales by geographic area, based on the location of the customer:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2014		2013
	United States	$	101,705	$	96,272
	International	12,505		8,746
	Total sales	$	114,210	$	105,018
	We classify our products into two categories: innovative fusion products and disruptive technology products. The following table represents total sales by product category:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2014		2013
	Innovative Fusion	$	66,770	$	61,322
	Disruptive Technology	47,440		43,696
	Total sales	$	114,210	$	105,018

BACKGROUND_AND_SUMMARY_OF_SIGN1

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2014
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held. All intercompany balances and transactions are eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
Marketable Securities	'
	Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper and asset-backed securities, and are classified as available-for-sale as of March 31, 2014. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
Revenue Recognition	'
	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2014
Intangible Assets Disclosure [Abstract]	'
Intangible Assets Acquired as Part of Business Combination	'
	A summary of intangible assets as of March 31, 2014 is presented below:
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Customer relationships & other intangibles	9.5	3,623		(962		)	2,661
	Patents	17	2,420		(237		)	2,183
	Total intangible assets		$	30,603	$	(1,199	)	$	29,404
	A summary of intangible assets as of December 31, 2013 is presented below:
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Customer relationships & other intangibles	9.5	3,623		(864		)	2,759
	Patents	17	2,420		(202		)	2,218
	Total intangible assets		$	30,603	$	(1,066	)	$	29,537

MARKETABLE_SECURITIES_Tables

MARKETABLE SECURITIES (Tables)	3 Months Ended
	Mar. 31, 2014
Marketable Securities [Abstract]	'
Marketable Securities	'
	The composition of our short-term and long-term marketable securities as of March 31, 2014 is as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	79,191	$	41	$	(2	)	$	79,230
	Corporate debt securities	Less than 1	66,299		28		(24		)	66,303
	Commercial paper	Less than 1	30,667		5		(1		)	30,671
	Total short-term marketable securities		$	176,157	$	74	$	(27	)	$	176,204
	Long-term:
	Municipal bonds	2-Jan	$	6,340	$	2	$	(2	)	$	6,340
	Corporate debt securities	2-Jan	10,582		9		(6		)	10,585
	Asset backed securities	2-Jan	7,224		2		—			7,226
	Total long-term marketable securities		$	24,146	$	13	$	(8	)	$	24,151
	Our short-term and long-term marketable securities as of December 31, 2013 were as follows:
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	77,342	$	17	$	(15	)	$	77,344
	Corporate debt securities	Less than 1	35,525		15		(11		)	35,529
	Commercial paper	Less than 1	36,083		6		—			36,089
	Total short-term marketable securities		$	148,950	$	38	$	(26	)	$	148,962
	Long-term:
	Municipal bonds	2-Jan	$	12,304	$	13	$	(1	)	$	12,316
	Corporate debt securities	2-Jan	17,533		27		—			17,560
	Asset backed securities	2-Jan	6,651		2		(1		)	6,652
	Total long-term marketable securities		$	36,488	$	42	$	(2	)	$	36,528

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Assets Measured on Recurring Basis	'
	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	March 31,		Level 1		Level 2		Level 3
		2014
	Assets
	Cash equivalents	$	30,686	$	12,359	$	18,327	$	—
	Municipal bonds	85,570		—		85,570		—
	Corporate debt securities	76,888		—		76,888		—
	Commercial paper	30,671		—		30,671		—
	Asset-backed securities	7,226		—		7,226		—
	Liabilities
	Acquisition-related contingent consideration	14,092		—		—		14,092
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2013
	Assets
	Cash equivalents	$	20,363	$	800	$	19,563	$	—
	Municipal bonds	89,660		—		89,660		—
	Corporate debt securities	53,089		—		53,089		—
	Commercial paper	36,089		—		36,089		—
	Asset-backed securities	6,652		—		6,652		—
	Liabilities
	Acquisition-related contingent consideration	14,177		—		—		14,177

INVENTORIES_Tables

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	(In thousands)	March 31, 2014		December 31, 2013
	Raw materials	$	1,870	$	1,369
	Work in process	2,411		2,820
	Finished goods	68,226		66,161
	Total inventories	$	72,507	$	70,350

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	(In thousands)	March 31,		December 31,
		2014		2013
	Compensation and other employee-related costs	$	11,852	$	17,428
	Legal and other settlements and expenses	26,509		23,765
	Non-income taxes	3,427		2,938
	Other	7,364		6,994
	Total accrued expenses	$	49,152	$	51,125

EQUITY_Tables

EQUITY (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Schedule of Issued and Outstanding Shares by Class	'
	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common			Class B	Total
					Common
	March 31, 2014	67,187,796			26,877,556	94,065,352
	December 31, 2013	66,065,197			27,377,556	93,442,753
Schedule of Stockholders Equity	'
	The following table summarizes changes in total equity:
		Three Months Ended
	(In thousands)	March 31,
		2014
	Total equity, beginning of period	$	472,360
	Net income	21,139
	Stock-based compensation	1,927
	Exercise of stock options	3,855
	Excess tax benefit of nonqualified stock options	2,786
	Other comprehensive loss	(2		)
	Total equity, end of period	$	502,065

EQUITY_Accumulated_Other_Compr

EQUITY Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income [Abstract]	'
Accumulated Other Comprehensive Income/(Loss), Net of Tax	'
	The tables below present the changes in each component of accumulated other comprehensive income/(loss), including current period other comprehensive income/(loss) and reclassifications out of accumulated other comprehensive income/(loss):
	(In thousands)	Unrealized gain/(loss) on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive income/(loss), net of tax, at December 31, 2013	$	32		$	(1,041	)	$	(1,009	)
	Other comprehensive loss before reclassifications	(5		)	(3		)	(8		)
	Amounts reclassified from accumulated other comprehensive income, net of tax	6			—			6
	Other comprehensive income/(loss), net of tax	1			(3		)	(2		)
	Accumulated other comprehensive income/(loss), net of tax, at March 31, 2014	$	33		$	(1,044	)	$	(1,011	)
	(In thousands)	Unrealized gain/(loss) on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive loss, net of tax, at December 31, 2012	$	—		$	(767	)	$	(767	)
	Other comprehensive loss	(18		)	(563		)	(581		)
	Other comprehensive loss, net of tax	(18		)	(563		)	(581		)
	Accumulated other comprehensive loss, net of tax, at March 31, 2013	$	(18	)	$	(1,330	)	$	(1,348	)

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Grants in Period, Weighted Average Grant Date Fair Value	'
	The weighted average grant date per share fair values of the options awarded to employees were as follows:
		Three Months Ended
		March 31,			March 31,
		2014			2013
	Weighted average grant date per share fair value	$	10.34		$	5.5
Summary of Stock Option Activity	'
	Stock option activity during the three months ended March 31, 2014 is summarized as follows:
		Option Shares(thousands)		Weighted average exercise price			Weighted average remaining contractual life (years)	Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2013	4,886		$	10.04
	Granted	794		24.55
	Exercised	(623	)	6.19
	Forfeited	(72	)	13.79
	Outstanding at March 31, 2014	4,985		$	12.78		7.4	$	68,826
	Exercisable at March 31, 2014	2,513		$	8.26		5.8	$	46,110
Stock Option Compensation Expense and Intrinsic Value Schedule	'
	Compensation expense related to stock options granted to employees and non-employees under the Plans and the intrinsic value of stock options exercised was as follows:
		Three Months Ended
	(In thousands)	March 31,			March 31,
		2014			2013
	Compensation expense related to stock options	$	1,927		$	1,312
	Intrinsic value of stock options exercised	11,283			6,920

RELATEDPARTY_TRANSACTIONS_Tabl

RELATED-PARTY TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Schedule of Related-Party Transactions	'
	We have purchased the following amounts of products and services from the supplier:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2014		2013
	Purchases from related-party supplier	$	4,850	$	5,132

SEGMENT_AND_GEOGRAPHIC_INFORMA1

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Revenue from External Customers by Geographical Area	'
	The following table represents total sales by geographic area, based on the location of the customer:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2014		2013
	United States	$	101,705	$	96,272
	International	12,505		8,746
	Total sales	$	114,210	$	105,018
Revenue from External Customers by Products and Services	'
	The following table represents total sales by product category:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2014		2013
	Innovative Fusion	$	66,770	$	61,322
	Disruptive Technology	47,440		43,696
	Total sales	$	114,210	$	105,018

BACKGROUND_AND_SUMMARY_OF_SIGN2

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (Minimum)	Mar. 31, 2014
Minimum	'
Summary of Significant Accounting Policies	'
Number of Products Launched Since Inception	120

ACQUISITIONS_Details

ACQUISITIONS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 23, 2013
			Acquisitions 2013
Business Acquisition	'	'	'
Net assets acquired	'	'	$16,800,000
Goodwill	$18,372,000	$18,372,000	$3,000,000

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Acquired Intangible Assets	'	'
Intangible assets, gross	$30,603	$30,603
Accumulated amortization	-1,199	-1,066
Intangible assets, net	29,404	29,537
Customer Relationships & Other Intangibles	'	'
Acquired Intangible Assets	'	'
Weighted average amortization period	'9 years 6 months	'9 years 6 months
Gross carrying amount	3,623	3,623
Accumulated amortization	-962	-864
Finite-lived intangible assets, net	2,661	2,759
Patents	'	'
Acquired Intangible Assets	'	'
Weighted average amortization period	'17 years	'17 years
Gross carrying amount	2,420	2,420
Accumulated amortization	-237	-202
Finite-lived intangible assets, net	2,183	2,218
In-Process Research & Development	'	'
Acquired Intangible Assets	'	'
Indefinite-lived intangible assets	$24,560	$24,560

MARKETABLE_SECURITIES_Details

MARKETABLE SECURITIES (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Short-term Marketable Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	$176,157	$148,950
Marketable Securities, Gross Unrealized Gains	74	38
Marketable Securities, Gross Unrealized Losses	-27	-26
Marketable Securities, Fair Value	176,204	148,962
Short-term Marketable Securities | Municipal Bonds	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	79,191	77,342
Marketable Securities, Gross Unrealized Gains	41	17
Marketable Securities, Gross Unrealized Losses	-2	-15
Marketable Securities, Fair Value	79,230	77,344
Short-term Marketable Securities | Municipal Bonds | Maximum	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Contractual Maturity	'1 year	'1 year
Short-term Marketable Securities | Corporate Debt Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	66,299	35,525
Marketable Securities, Gross Unrealized Gains	28	15
Marketable Securities, Gross Unrealized Losses	-24	-11
Marketable Securities, Fair Value	66,303	35,529
Short-term Marketable Securities | Corporate Debt Securities | Maximum	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Contractual Maturity	'1 year	'1 year
Short-term Marketable Securities | Commercial Paper	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	30,667	36,083
Marketable Securities, Gross Unrealized Gains	5	6
Marketable Securities, Gross Unrealized Losses	-1	0
Marketable Securities, Fair Value	30,671	36,089
Short-term Marketable Securities | Commercial Paper | Maximum	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Contractual Maturity	'1 year	'1 year
Long-term Marketable Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	24,146	36,488
Marketable Securities, Gross Unrealized Gains	13	42
Marketable Securities, Gross Unrealized Losses	-8	-2
Marketable Securities, Fair Value	24,151	36,528
Long-term Marketable Securities | Municipal Bonds	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	6,340	12,304
Marketable Securities, Gross Unrealized Gains	2	13
Marketable Securities, Gross Unrealized Losses	-2	-1
Marketable Securities, Fair Value	6,340	12,316
Long-term Marketable Securities | Municipal Bonds | Minimum	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Contractual Maturity	'1 year	'1 year
Long-term Marketable Securities | Municipal Bonds | Maximum	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Contractual Maturity	'2 years	'2 years
Long-term Marketable Securities | Corporate Debt Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	10,582	17,533
Marketable Securities, Gross Unrealized Gains	9	27
Marketable Securities, Gross Unrealized Losses	-6	0
Marketable Securities, Fair Value	10,585	17,560
Long-term Marketable Securities | Corporate Debt Securities | Minimum	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Contractual Maturity	'1 year	'1 year
Long-term Marketable Securities | Corporate Debt Securities | Maximum	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Contractual Maturity	'2 years	'2 years
Long-term Marketable Securities | Asset-backed Securities	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Amortized Cost Basis	7,224	6,651
Marketable Securities, Gross Unrealized Gains	2	2
Marketable Securities, Gross Unrealized Losses	0	-1
Marketable Securities, Fair Value	$7,226	$6,652
Long-term Marketable Securities | Asset-backed Securities | Minimum	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Contractual Maturity	'1 year	'1 year
Long-term Marketable Securities | Asset-backed Securities | Maximum	'	'
Schedule of Marketable Securities	'	'
Marketable Securities, Contractual Maturity	'2 years	'2 years

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (Fair Value, Measurements, Recurring, USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	$30,686,000	$20,363,000
Acquisition-related contingent consideration	14,092,000	14,177,000
Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Reclassification adjustment at December 31, 2013	18,300,000	'
Cash equivalents	12,359,000	800,000
Acquisition-related contingent consideration	0	0
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	18,327,000	19,563,000
Acquisition-related contingent consideration	0	0
Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Cash equivalents	0	0
Acquisition-related contingent consideration	14,092,000	14,177,000
Municipal Bonds | Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	85,570,000	89,660,000
Municipal Bonds | Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Municipal Bonds | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	85,570,000	89,660,000
Municipal Bonds | Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Corporate Debt Securities | Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	76,888,000	53,089,000
Corporate Debt Securities | Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Corporate Debt Securities | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	76,888,000	53,089,000
Corporate Debt Securities | Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Commercial Paper | Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	30,671,000	36,089,000
Commercial Paper | Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Commercial Paper | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	30,671,000	36,089,000
Commercial Paper | Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Asset-backed Securities | Estimate of Fair Value, Fair Value Disclosure	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	7,226,000	6,652,000
Asset-backed Securities | Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	0	0
Asset-backed Securities | Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	7,226,000	6,652,000
Asset-backed Securities | Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring Basis	'	'
Marketable Securities	$0	$0

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw Materials	$1,870	$1,369
Work in process	2,411	2,820
Finished goods	68,226	66,161
Total inventories	$72,507	$70,350

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Compensation and other employee-related costs	$11,852	$17,428
Legal and other settlements and expenses	26,509	23,765
Accrued non-income taxes	3,427	2,938
Other	7,364	6,994
Total accrued expenses	$49,152	$51,125

DEBT_Details

DEBT (Details) (Revolving Credit Facility, USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument	'	'
Credit facility, current borrowing capacity	$50	'
Credit facility, maximum borrowing capacity	75	'
Revolving credit facility, unused commitment fee percentage	0.10%	'
Line of Credit, Termination Period Without Penalty	'	'10 days
Fluctuating Rate Per Annum	'	'
Debt Instrument	'	'
Credit facility, variable rate	'LIBOR	'
Credit facility, period of variable rate	'1 month	'
Credit facility, basis spread on variable rate	0.75%	'
Fixed Rate	'	'
Debt Instrument	'	'
Credit facility, variable rate	'LIBOR	'
Credit facility, basis spread on variable rate	0.75%	'
Fixed Rate | Minimum	'	'
Debt Instrument	'	'
Credit facility, period of variable rate	'1 month	'
Fixed Rate | Maximum	'	'
Debt Instrument	'	'
Credit facility, period of variable rate	'3 months	'
Letter of Credit	'	'
Debt Instrument	'	'
Credit facility, maximum borrowing capacity	$25	'

EQUITY_Textuals_Details

EQUITY (Textuals) (Details)	Mar. 31, 2014	Dec. 31, 2013
Class of Stock	'	'
Common stock, shares authorized	785,000,000	785,000,000
Common Class A	'	'
Class of Stock	'	'
Common stock, shares authorized	500,000,000	'
Common Class B	'	'
Class of Stock	'	'
Common stock, shares authorized	275,000,000	'
Common Class C	'	'
Class of Stock	'	'
Common stock, shares authorized	10,000,000	'

EQUITY_Schedule_of_Issued_and_

EQUITY (Schedule of Issued and Outstanding Shares) (Details)	Mar. 31, 2014	Dec. 31, 2013
Class of Stock	'	'
Common stock, shares issued	94,065,352	93,442,753
Common stock, shares outstanding	94,065,352	93,442,753
Class A Common	'	'
Class of Stock	'	'
Common stock, shares issued	67,187,796	66,065,197
Common stock, shares outstanding	67,187,796	66,065,197
Class B Common	'	'
Class of Stock	'	'
Common stock, shares issued	26,877,556	27,377,556
Common stock, shares outstanding	26,877,556	27,377,556

EQUITY_Stockholders_Equity_Rol

EQUITY Stockholders' Equity Rollforward (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Increase (Decrease) in Stockholders' Equity	'	'
Total stockholders' equity, beginning of period	$472,360	'
Net income	21,139	19,891
Stock-based compensation	1,927	'
Exercise of stock options	3,855	'
Excess tax benefit of nonqualified stock options	2,786	'
Other comprehensive loss	-2	-581
Total stockholders' equity, end of period	$502,065	'

EQUITY_Accumulated_Other_Compr1

EQUITY Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Accumulated other comprehensive income/(loss), net of tax	($1,011)	($1,348)	($1,009)	($767)
Other comprehensive loss before reclassifications	-8	-581	'	'
Amounts reclassified from accumulated other comprehensive income, net of tax	6	'	'	'
Other comprehensive income/(loss), net of tax	-2	-581	'	'
Foreign Currency Translation Adjustment	'	'	'	'
Accumulated other comprehensive income/(loss), net of tax	-1,044	-1,330	-1,041	-767
Other comprehensive loss before reclassifications	-3	-563	'	'
Amounts reclassified from accumulated other comprehensive income, net of tax	0	'	'	'
Other comprehensive income/(loss), net of tax	-3	-563	'	'
Unrealized Gain/(Loss) on Marketable Securities, Net of Tax	'	'	'	'
Accumulated other comprehensive income/(loss), net of tax	33	-18	32	0
Other comprehensive loss before reclassifications	-5	-18	'	'
Amounts reclassified from accumulated other comprehensive income, net of tax	6	'	'	'
Other comprehensive income/(loss), net of tax	$1	($18)	'	'

STOCKBASED_COMPENSATION_Textua

STOCK-BASED COMPENSATION (Textuals) (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award	'
Number of stock plans	3
Stock Options	'
Share-based Compensation Arrangement by Share-based Payment Award	'
Maximum contractual term	'10 years
Award vesting period (in years)	'4 years
Unrecognized compensation expense, unvested stock options	$16.40
Weighted average period of recognition, unvested stock options	'3 years
2012 Equity Incentive Plan	'
Share-based Compensation Arrangement by Share-based Payment Award	'
Base number of shares that may be issuable under stock plan	3,076,923
2012 Equity Incentive Plan | Maximum	'
Share-based Compensation Arrangement by Share-based Payment Award	'
Number of shares available for grant	10,769,230
Annual percentage limit for incremental shares that may be issued	3.00%
2012 Equity Incentive Plan | Common Class A	'
Share-based Compensation Arrangement by Share-based Payment Award	'
Number of shares available for grant	6,533,666

STOCKBASED_COMPENSATION_Grant_

STOCK-BASED COMPENSATION (Grant Date Fair Values of Options Awarded to Employees) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Weighted average grant date per share fair value	$10.34	$5.50

STOCKBASED_COMPENSATION_Stock_

STOCK-BASED COMPENSATION (Stock Option Activity) (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding	'
Number of shares outstanding beginning balance	4,886
Number of shares granted	794
Number of shares exercised	-623
Number of shares forfeited	-72
Number of shares outstanding ending balance	4,985
Number of shares exercisable	2,513
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	'
Weighted average exercise price per share outstanding beginning balance	$10.04
Weighted average exercise price per share granted	$24.55
Weighted average exercise price per share exercised	$6.19
Weighted average exercise price per share forfeited	$13.79
Weighted average exercise price per share outstanding ending balance	$12.78
Weighted average exercise price per share exercisable	$8.26
Weighted average remaining contractual life outstanding	'7 years 4 months 24 days
Weighted average remaining contractual life exercisable	'5 years 9 months 18 days
Aggregate intrinsic value outstanding	$68,826
Aggregate intrinsic value exercisable	$46,110

STOCKBASED_COMPENSATION_Compen

STOCK-BASED COMPENSATION (Compensation Expense Related to Stock Options and Their Intrinsic Values) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Compensation expense related to stock options	$1,927	$1,312
Intrinsic value of stock options exercised	$11,283	$6,920

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Effective income tax rate	34.90%	32.60%
Tax credit applicable to 2012 recognized in 2013 due to retroactive change in tax law	'	$0.80
Effective tax rate, estimated impact for legislation not yet enacted	0.70%	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Jul. 31, 2011

Jul. 31, 2011

Oct. 31, 2010

Oct. 31, 2010

Dec. 31, 2013

Mar. 31, 2014

Feb. 20, 2013

Dec. 31, 2013

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation

NuVasive, Inc. Litigation

NuVasive, Inc. Litigation

Bianco

Altus Partners, LLC Litigation

Altus Partners, LLC Litigation

N-Spine and Synthes Litigation

claim

Minimum

claim

Minimum

Minimum

Minimum

claim

claim

claim

claim

Loss Contingencies

'

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency, Pending Claims, Number

'

'

'

'

3

1

3

1

'

'

1

1

Damages awarded

'

'

'

$16,000,000

'

'

'

'

'

'

'

'

Combined litigation loss

'

'

'

19,500,000

'

'

'

'

4,300,000

'

'

'

Provision for litigation, net - cost of goods sold

'

'

'

1,300,000

'

'

'

'

'

'

'

'

Provision for litigation, net

$2,535,000

$50,000

$500,000

$18,200,000

'

'

'

'

'

$2,000,000

'

'

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Related Party Transactions [Abstract]	'	'	'
Accounts payable to related-party	$3,840	'	$2,656
Purchases from related-party supplier	$4,850	$5,132	'

SEGMENT_AND_GEOGRAPHIC_INFORMA2

SEGMENT AND GEOGRAPHIC INFORMATION (Geographic Location) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenues from External Customers	'	'
Total sales	$114,210	$105,018
United States	'	'
Revenues from External Customers	'	'
Total sales	101,705	96,272
International	'	'
Revenues from External Customers	'	'
Total sales	$12,505	$8,746

SEGMENT_AND_GEOGRAPHIC_INFORMA3

SEGMENT AND GEOGRAPHIC INFORMATION (Products) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
	segments
	categories
Revenue from External Customer	'	'
Total sales	$114,210	$105,018
Textuals [Abstract]	'	'
Number of reportable segments	1	'
Number of product categories	2	'
Innovative Fusion	'	'
Revenue from External Customer	'	'
Total sales	66,770	61,322
Disruptive Technology	'	'
Revenue from External Customer	'	'
Total sales	$47,440	$43,696